A PYMNTS Company

India: CCI imposes fine on GlaxoSmithKline Pharmaceutical

By  |  June 7, 2015

Competition Commission has slapped a penalty of Rs 64 crore on drugmakers GlaxoSmithKline Pharmaceuticals and Sanofi for collusive bidding in supply of a meningitis vaccine to the government for Haj pilgrims.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The matter relates to supply of polysaccharide Quadrivalent Meningococcal Meningitis (QMMV) vaccines and the complaint was filed by Bio-Med Pvt Ltd, which also makes this drug. The complaint was also filed against the Health and Family Welfare Ministry.

    Every year, the government invites tenders for purchase of meningitis vaccine that is required to be administered upon Haj pilgrims.

    Full content: The Economic Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.